Business Context and Reporting Period
This Form 8-K was filed by Aziyo Biologics, Inc. (trading as AZYO) on June 7, 2021. The report addresses a voluntary recall of a single donor lot of its FiberCel Fiber Viable Bone Matrix, a human tissue-based bone repair product used in orthopedic and spinal procedures.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures. However, it explicitly states that the Company is suspending its revenue guidance for the full year 2021, which was previously announced on May 4, 2021, due to the uncertainty surrounding the recall and the suspension of FiberCel sales.
Material Changes and Events
- Voluntary Recall: On June 2, 2021, the Company issued a recall for 154 units of FiberCel derived from a single donor. These units were shipped to facilities in 20 states.
- Product Suspension: Sales of FiberCel have been suspended by the distributor until further notice as a precautionary measure.
- Health Concerns: The recall follows reports of post-surgical infections in patients treated with the product, including cases testing positive for tuberculosis (Mycobacterium tuberculosis).
- Investigation: Aziyo is investigating the source of the infections in coordination with its distributor, the U.S. Food and Drug Administration (FDA), and the U.S. Centers for Disease Control and Prevention (CDC).
- Scope: The Company currently has no reason to believe any other units of FiberCel are affected.
Guidance, Outlook, and Risks
Management has suspended its full-year 2021 revenue guidance due to the potential business impact of the recall and sales suspension. The filing includes standard forward-looking statement disclaimers, noting that actual results may differ materially due to risks including technical complexity, quality control requirements, and product misuse. The Company undertakes no obligation to update forward-looking statements except as required by law.
Investor Verification Checklist
- Verify the status of the FDA and CDC investigation regarding the tuberculosis infections.
- Monitor for updates on the timeline for resuming FiberCel sales.
- Review the Company's next financial report for the impact of the sales suspension on actual revenue versus the suspended guidance.
- Check for any additional recalls or regulatory actions beyond the single donor lot mentioned.